IL4 and osteoarthritis: Recently, a randomized double-blind placebo-clinical trial by arthrocen showed that its oral administration diminished TNF-α and IL-17 while it increased anti-inflammatory IL-4 and IL-10 blood levels in patients with osteoarthritis [11].